Loading...
XNASINCY
Market cap13bUSD
Dec 24, Last price  
69.91USD
1D
0.10%
1Q
10.58%
Jan 2017
-30.28%
Name

Incyte Corp

Chart & Performance

D1W1MN
XNAS:INCY chart
P/E
22.54
P/S
3.64
EPS
3.10
Div Yield, %
0.00%
Shrs. gr., 5y
0.94%
Rev. gr., 5y
14.45%
Revenues
3.70b
+8.87%
14,146,0007,846,00027,643,00034,440,0003,919,0009,265,000169,878,00094,455,000297,059,000354,947,000511,495,000753,751,0001,105,719,0001,536,216,0001,881,883,0002,158,759,0002,666,702,0002,986,267,0003,394,635,0003,695,649,000
Net income
598m
+75.42%
-164,817,000-103,043,000-74,166,000-86,881,000-178,920,000-211,870,000-31,846,000-186,540,000-44,320,000-83,147,000-48,481,0006,531,000104,222,000-313,142,000109,493,000446,906,000-295,697,000948,581,000340,660,000597,599,000
CFO
496m
-48.81%
-114,667,000-101,872,000-50,367,000-92,694,000-140,860,00012,358,00097,938,000-161,715,000-94,830,0009,180,00026,256,00086,536,000304,756,000-92,988,000336,227,000710,656,000-124,599,000749,488,000969,941,000496,487,000
Earnings
Feb 11, 2025

Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
URL
https://www.incyte.com/
IPO date
Dec 06, 1993
Employees
2,324
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,695,649
8.87%
3,394,635
13.67%
2,986,267
11.98%
Cost of revenue
3,043,894
2,795,073
2,348,730
Unusual Expense (Income)
NOPBT
651,755
599,562
637,537
NOPBT Margin
17.64%
17.66%
21.35%
Operating Taxes
236,616
188,456
(378,137)
Tax Rate
36.30%
31.43%
NOPAT
415,139
411,106
1,015,674
Net income
597,599
75.42%
340,660
-64.09%
948,581
-420.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,286
34,814
28,686
BB yield
-0.05%
-0.19%
-0.18%
Debt
Debt current
9,125
11,374
13,189
Long-term debt
67,449
66,524
68,534
Deferred revenue
(42,562)
(40,378)
Other long-term liabilities
322,729
221,000
244,000
Net debt
(3,767,185)
(3,294,743)
(2,487,735)
Cash flow
Cash from operating activities
496,487
969,941
749,488
CAPEX
(47,486)
(77,833)
(181,006)
Cash from investing activities
(207,677)
(78,542)
(207,699)
Cash from financing activities
(20,033)
(794)
6,176
FCF
403,699
396,966
852,282
Balance
Cash
3,656,043
3,238,965
2,348,192
Long term investments
187,716
133,676
221,266
Excess cash
3,658,977
3,202,909
2,420,145
Stockholders' equity
173,715
(421,922)
(797,107)
Invested Capital
5,377,138
5,008,007
4,818,189
ROIC
7.99%
8.37%
21.46%
ROCE
11.74%
12.95%
15.70%
EV
Common stock shares outstanding
225,928
223,958
222,074
Price
62.79
-21.83%
80.32
9.43%
73.40
-15.61%
Market cap
14,186,019
-21.14%
17,988,307
10.36%
16,300,232
-14.06%
EV
10,418,834
14,693,564
13,812,497
EBITDA
734,415
667,417
695,381
EV/EBITDA
14.19
22.02
19.86
Interest
2,551
2,666
1,908
Interest/NOPBT
0.39%
0.44%
0.30%